Amarin Co. plc (NASDAQ:AMRN – Get Free Report) was the recipient of a large growth in short interest during the month of June. As of June 15th, there was short interest totalling 19,020,000 shares, a growth of 20.3% from the May 31st total of 15,810,000 shares. Based on an average daily volume of 1,490,000 shares, the short-interest ratio is currently 12.8 days.
Amarin Stock Performance
Shares of Amarin stock traded up $0.02 during trading hours on Tuesday, reaching $0.71. The company’s stock had a trading volume of 949,347 shares, compared to its average volume of 1,830,627. The company’s 50 day simple moving average is $0.81 and its 200 day simple moving average is $0.95. Amarin has a one year low of $0.63 and a one year high of $1.49. The stock has a market cap of $289.52 million, a P/E ratio of -5.88 and a beta of 1.95.
Amarin (NASDAQ:AMRN – Get Free Report) last released its earnings results on Wednesday, May 1st. The biopharmaceutical company reported ($0.02) EPS for the quarter, beating the consensus estimate of ($0.04) by $0.02. Amarin had a negative net margin of 18.96% and a negative return on equity of 9.48%. The firm had revenue of $56.52 million for the quarter, compared to analysts’ expectations of $51.34 million. During the same quarter last year, the company earned ($0.04) EPS. On average, sell-side analysts predict that Amarin will post -0.18 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
Get Our Latest Analysis on AMRN
Hedge Funds Weigh In On Amarin
A number of institutional investors have recently modified their holdings of AMRN. GSA Capital Partners LLP boosted its stake in shares of Amarin by 74.4% in the 1st quarter. GSA Capital Partners LLP now owns 1,482,540 shares of the biopharmaceutical company’s stock valued at $1,321,000 after purchasing an additional 632,497 shares in the last quarter. BNP Paribas Financial Markets increased its stake in Amarin by 104.8% during the 1st quarter. BNP Paribas Financial Markets now owns 932,173 shares of the biopharmaceutical company’s stock worth $830,000 after purchasing an additional 476,996 shares in the last quarter. Simplicity Wealth LLC bought a new position in shares of Amarin during the 1st quarter worth approximately $418,000. Hayek Kallen Investment Management grew its stake in shares of Amarin by 63.3% in the fourth quarter. Hayek Kallen Investment Management now owns 1,016,760 shares of the biopharmaceutical company’s stock valued at $885,000 after buying an additional 394,117 shares in the last quarter. Finally, Gilliland Jeter Wealth Management LLC bought a new position in shares of Amarin in the fourth quarter valued at $64,000. Institutional investors own 22.25% of the company’s stock.
Amarin Company Profile
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.
See Also
- Five stocks we like better than Amarin
- Election Stocks: How Elections Affect the Stock Market
- RXO Shares Surge Following New Acquisition Deal
- 5 discounted opportunities for dividend growth investors
- 3 Stock Dips Insiders Are Buying: Vestis, Shenandoah, Treace
- How to Read Stock Charts for Beginners
- Biotech Stock Breakout: IBB Eyes Resistance with Amgen and Vertex
Receive News & Ratings for Amarin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin and related companies with MarketBeat.com's FREE daily email newsletter.